Compare AbCellera Biologics Inc (ABCL) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Keysight Technologies Inc — how do they compare? AbCellera Biologics Inc trades at $9.94 (market cap $2.99B), while Keysight Technologies Inc trades at $352.6 (market cap $58.74B). The key difference: Keysight Technologies Inc is far larger — about 19.6× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Keysight Technologies Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | KEYS | |
|---|---|---|
Market Cap | $2.99B | $58.74B |
Sector | Health | Technology |
52-Week High | $9.76 | $373.34 |
52-Week Low | $2.78 | $158.51 |
Enterprise Value | $2.58B | $59.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
Keysight Technologies (KEYS) trades at $335.41, down 1.63% on the day, with a bullish technical outlook and strong analyst support. The stock exhibits robust fundamentals, including a 17.31% net income margin and consistent earnings beats, with Q1 2026 EPS of $2.87 surpassing the $2.32 estimate. Recent developments include new product launches and strategic collaborations, such as the certification of electromagnetic design software for Intel's latest processes (Business Wire, 2026-07-27).
The outlook for KEYS is positive, driven by earnings growth and innovation in test and measurement solutions. Key opportunities include expansion in 5G and cybersecurity markets, though risks involve high valuation multiples and competitive pressures. The consensus price target of $396.56 implies significant upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
